Latest Propel Bio Management, LLC Stock Portfolio
Propel Bio Management, LLC Performance:
2024 Q3: 17.19%YTD: 40.52%
Performance for 2024 Q3 is 17.19%, and YTD is 40.52%.
About Propel Bio Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Propel Bio Management, LLC reported an equity portfolio of $172.4 Millions as of 30 Sep, 2024.
The top stock holdings of Propel Bio Management, LLC are APLT, PAGP, PHAT. The fund has invested 32.4% of it's portfolio in APPLIED THERAPEUTICS INC and 13.7% of portfolio in PLAINS GP HOLDINGS LP-CL.
The fund managers got completely rid off FULCRUM THERAPEUTICS INC (FULC), KAYNE ANDERSON ENERGY INF and TREVI THERAPEUTICS INC (TRVI) stocks. They significantly reduced their stock positions in ABEONA THERAPEUTICS INC (ABEO), VERRICA PHARMACEUTICALS I (VRCA) and PLAINS GP HOLDINGS LP-CL (PAGP). Propel Bio Management, LLC opened new stock positions in ZEVRA THERAPEUTICS INC and COMPASS PATHWAYS LTD (CMPS). The fund showed a lot of confidence in some stocks as they added substantially to SYNDAX PHARMACEUTICALS IN (SNDX), ARDELYX INC (ARDX) and AKERO THERAPEUTICS INC (AKRO).
The top stock holdings of Propel Bio Management, LLC are APLT, PAGP, PHAT. The fund has invested 32.4% of it's portfolio in APPLIED THERAPEUTICS INC and 13.7% of portfolio in PLAINS GP HOLDINGS LP-CL.
The fund managers got completely rid off FULCRUM THERAPEUTICS INC (FULC), KAYNE ANDERSON ENERGY INF and TREVI THERAPEUTICS INC (TRVI) stocks. They significantly reduced their stock positions in ABEONA THERAPEUTICS INC (ABEO), VERRICA PHARMACEUTICALS I (VRCA) and PLAINS GP HOLDINGS LP-CL (PAGP). Propel Bio Management, LLC opened new stock positions in ZEVRA THERAPEUTICS INC and COMPASS PATHWAYS LTD (CMPS). The fund showed a lot of confidence in some stocks as they added substantially to SYNDAX PHARMACEUTICALS IN (SNDX), ARDELYX INC (ARDX) and AKERO THERAPEUTICS INC (AKRO).
Propel Bio Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Propel Bio Management, LLC made a return of 17.19% in the last quarter. In trailing 12 months, it's portfolio return was 70.09%.
New Buys
| Ticker | $ Bought |
|---|---|
| zevra therapeutics inc | 1,248,330 |
| compass pathways ltd | 504,000 |
| maat pharma saca | 17,786 |
New stocks bought by Propel Bio Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| syndax pharmaceuticals in | 60.05 |
| ardelyx inc | 15.83 |
| akero therapeutics inc | 4.87 |
Additions to existing portfolio by Propel Bio Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| abeona therapeutics inc | -50.00 |
| verrica pharmaceuticals i | -18.83 |
| plains gp holdings lp-cl | -7.29 |
Propel Bio Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cybin inc | -230,350 |
| fulcrum therapeutics inc | -4,650,000 |
| fidelity inv mmtrsy 1 680 | -317,014 |
| trevi therapeutics inc | -774,800 |
| kayne anderson energy inf | -1,518,850 |
| maat pharma saca | -9,752 |
Propel Bio Management, LLC got rid off the above stocks
Sector Distribution
Propel Bio Management, LLC has about 82.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 82.8 |
| Energy | 13.7 |
| Others | 3.5 |
Market Cap. Distribution
Propel Bio Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 60.8 |
| MID-CAP | 25.3 |
| MICRO-CAP | 9.7 |
| UNALLOCATED | 3.5 |
Stocks belong to which Index?
About 34% of the stocks held by Propel Bio Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 66 |
| RUSSELL 2000 | 34 |
Propel Bio Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Propel Bio Management, LLC
Propel Bio Management, LLC has 21 stocks in it's portfolio. About 90.8% of the portfolio is in top 10 stocks. ATHA proved to be the most loss making stock for the portfolio. APLT was the most profitable stock for Propel Bio Management, LLC last quarter.
Last Reported on: 13 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABEO | abeona therapeutics inc | 2.29 | 624,022 | 3,943,820 | reduced | -50.00 | ||
| ACHV | achieve life sciences inc | 6.74 | 2,453,090 | 11,627,700 | unchanged | 0.00 | ||
| AKRO | akero therapeutics inc | 5.72 | 343,729 | 9,861,580 | added | 4.87 | ||
| APLT | applied therapeutics inc | 32.38 | 6,567,860 | 55,826,800 | unchanged | 0.00 | ||
| ARDX | ardelyx inc | 4.28 | 1,070,950 | 7,378,820 | added | 15.83 | ||
| ATHA | athira pharma inc | 0.39 | 1,492,790 | 665,785 | unchanged | 0.00 | ||
| CMPS | compass pathways ltd | 0.29 | 80,000 | 504,000 | new | |||
| CYBN | cybin inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EIGR | eiger biopharmaceuticals | 0.72 | 146,381 | 1,244,240 | unchanged | 0.00 | ||
| FULC | fulcrum therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KURA | kura oncology inc | 1.47 | 130,000 | 2,540,200 | unchanged | 0.00 | ||
| KYMR | kymera therapeutics inc | 1.55 | 56,359 | 2,667,470 | unchanged | 0.00 | ||
| MDGL | madrigal pharmaceuticals | 5.30 | 43,032 | 9,132,250 | unchanged | 0.00 | ||
| PAGP | plains gp holdings lp-cl | 13.65 | 1,272,360 | 23,538,700 | reduced | -7.29 | ||
| PHAT | phathom pharmaceuticals i | 9.12 | 869,927 | 15,728,300 | unchanged | 0.00 | ||
| RNA | avidity biosciences inc | 4.76 | 178,500 | 8,198,500 | unchanged | 0.00 | ||
| SNDX | syndax pharmaceuticals in | 1.49 | 133,259 | 2,565,240 | added | 60.05 | ||
| TCRX | tscan therapeutics inc | 6.03 | 2,087,140 | 10,394,000 | unchanged | 0.00 | ||
| TRVI | trevi therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VRCA | verrica pharmaceuticals i | 0.29 | 344,937 | 500,159 | reduced | -18.83 | ||